Hualan Biological Engineering (002007) Stock Overview
Engages in the research, development, production, and sale of biological products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002007 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hualan Biological Engineering Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.10 |
| 52 Week High | CN¥18.39 |
| 52 Week Low | CN¥11.72 |
| Beta | 0.36 |
| 1 Month Change | 1.16% |
| 3 Month Change | -10.34% |
| 1 Year Change | -22.58% |
| 3 Year Change | -42.77% |
| 5 Year Change | -64.39% |
| Change since IPO | -27.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002007 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.1% | -4.2% | -4.7% |
| 1Y | -22.6% | -23.8% | 10.6% |
Return vs Industry: 002007 exceeded the CN Biotechs industry which returned -23.8% over the past year.
Return vs Market: 002007 underperformed the CN Market which returned 10.6% over the past year.
Price Volatility
| 002007 volatility | |
|---|---|
| 002007 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 12.3% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 002007 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002007's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 4,117 | Bei Fan | www.hualanbio.com |
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines.
Hualan Biological Engineering Inc. Fundamentals Summary
| 002007 fundamental statistics | |
|---|---|
| Market cap | CN¥23.92b |
| Earnings (TTM) | CN¥857.61m |
| Revenue (TTM) | CN¥4.49b |
Is 002007 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002007 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.49b |
| Cost of Revenue | CN¥2.01b |
| Gross Profit | CN¥2.48b |
| Other Expenses | CN¥1.62b |
| Earnings | CN¥857.61m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 29, 2026
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 55.16% |
| Net Profit Margin | 19.10% |
| Debt/Equity Ratio | 0% |
How did 002007 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 20:43 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hualan Biological Engineering Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethan Cui | BofA Global Research |
| Fusheng Cheung | China Galaxy International Securities (Hong Kong) |
| Fang Quan | China International Capital Corporation Limited |